Introducing
Prezi AI.
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
Loading…
Hambrick and Fredrickson's Strategy Model
23
Transcript
- Manufacturing and selling of Pharmaceutical Formulations and API's.
- The channels of delivery is based upon distributors and wholesalers.
- Market segments are hospitals and pharmacy.
- Widely expanded in the US, CANADA and BRAZIL in terms of geographical area.
- Investment in building specialty teams in the US
- Entry of complex or differentiated generics into market.
- SPARC's ELEPSIA XR (Levetiracetam Extented Release tablets)
- Alliance with Japan's Mitsubishi Tanabe Pharma Corp.
- Acquisition over rival Ranbaxy Laboratories.
- The US alone has over 5 million treatments annually with DUSA having 5% share of it.
- Expanding new markets.
- Protect market shares by continuous innovation in Proactive Marketing and Defence marketing.
- Timely product launches focus on fast growing acquisitions due to minor price increase on new drug launches.
- Economics of scale as they provide high quality affordable medicines.
- Business model of exclusive marketing rights and co-marketing.
- Full range of global and local commercial capabilities.
- Track record of successful product launches.
Arenas
Economic Logic
Vehicles
Staging
- In 1961 Ranbaxy incorporated as a company with Sun Pharma.
- In 1983 Sun Pharma established with five psychiatry wards.
- In 2007 Sun Pharma demerges SPARC first pure research company
- In 2011 merged with Ranbaxy it crossed US $ 2 billion.
Differentiators
Choose a template
Learn more about creating dynamic, engaging presentations with Prezi